Horizon制药公共 HZNP 深 沪
已收盘 10-06 16:00:00 美东时间
116.30
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 116.30
- 总市值 2663.27万
- 52周最高 116.38
- 市盈率 静 52.46
- 换手率 0.00%
- 52周最低 60.03
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 120.535
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.965
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Hemab Therapeutics appoints Keli Walbert to its Board of Directors, effective September 24, 2026. With over 20 years of commercial leadership experience in biopharmaceuticals, Walbert brings expertise in launching therapies for high-unmet-need conditions. Her appointment strengthens Hemab's Board as the company advances its pipeline for treating bleeding disorders. Walbert previously led commercial launches at Horizon Therapeutics, AbbVie, and ot...
09-24 20:01
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer to lead its commercial strategy and preparations for the potential 2027 launch of risto-cel. Foster, with over 25 years of experience in biopharmaceuticals, including successful leadership at Horizon Therapeutics and Ardelyx, will help build a strong commercial organization and advance the company's precision genetic medicines pipeline.
09-01 11:00
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
Monopar Therapeutics Inc. appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs to lead preparations for FDA approval of ALXN1840, a potential treatment for Wilson disease. Two abstracts on ALXN1840 have been accepted for presentation at the AASLD – The Liver Meeting® 2026. ALXN1840 is a first-in-class albumin tripartite complex activator that addresses unmet needs in Wilson disease by rapidly mobilizing and sequest...
08-19 12:00
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma announced the transition of its board, with four independent directors resigning, and the appointment of Daniel Camardo and Viola Meehan. Camardo, a former CEO with a track record of successful drug launches, and Meehan, a seasoned CFO with expertise in strategic finance, will bring critical experience to support the company's growth and late-stage clinical capabilities. The company emphasized their contributions to advancing transf...
06-02 20:05
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) on Monday announced the appointment of Christopher Murphy as Chief Financial Officer. Murphy, previously, served as CFO and CBO of Third Harmonic Bio. Before Third Harmonic, he serve...
05-11 21:25
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma appoints Shao-Lee Lin, M.D., Ph.D., as CEO and President. Dr. Lin brings over 25 years of biopharmaceutical leadership experience, including successful IPOs and regulatory approvals. She will lead the advancement of CUE-401, a novel therapeutic for autoimmune diseases, and expand the clinical pipeline. Cue Biopharma focuses on developing innovative therapies targeting T cells to address autoimmune and inflammatory conditions.
04-30 20:05
